Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of subcutaneous pertuzumab + trastuzumab fixed-dose combination in HER2-positive early breast cancer
CTR20191171Phase 3Completed
- Sponsor
- Roche
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pertuzumab, trastuzumab in breast cancer, sponsored by Roche. Started Feb 2020; status: completed.
02
Drugs
pertuzumabtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20191171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191171.